
7 Hills Pharma LLC Profile last edited on: 9/21/2022
CAGE: 78U51
UEI: CJJ6DE7APKY6
Business Identifier: Novel immunotherapies to improve treatment of drug resistant cancers and prevention of infectious diseases Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 18
County: Harris
Congr. District: 18
County: Harris
Public Profile
Currently having a presence in JLabs Houston, 7 Hills Pharma LLC is an immuno-oncology company focused on developing drugs for drug resistant cancers. Despite improving cure rates in rare cancers, the promise of immunotherapy and cell therapy is yet to be realized for solid tumors such as lung, colon, and other cancers. 7 Hills is developing cost-effective technologies that modulate the immune system with the objective of increasing the effectiveness of immune checkpoint blockade, doptive cell therapy, and cord blood transplant to treat solid tumors and orphan genetic diseases. A key factor limiting the success of immuno-oncology therapy and adoptive cell therapy is the relatively low number of tumor specific T cells that physically enter a solid tumor. Tumors secrete agents that suppress the immune response and can actively alter their cell surface to prevent specific T cells from binding them and killing them. 7HP compounds are designed to overcome the ability of a tumor to evade the immune response by imparting on tumor specific T cells the capability to localize to, and efficiently kill, tumor cells. Cord Blood Program Cord blood stem cell transplant is potentially curative for a variety of hematologic cancers and genetic diseases. However, the low number of stem cells in cord blood preparations limits their use primarily to pediatric patients, and can result in an increased risk of opportunistic infections, increased hospital costs, and high graft failure rates. 7HP compounds are designed to act as cellular glue, promoting cord blood stem cell adhesion and engraftment into the bone marrow resulting in improved patient outcomes.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 2 | NIH | $1,997,167 | |
Project Title: Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection | ||||
2023 | 1 | NIH | $928,224 | |
Project Title: 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination | ||||
2023 | 1 | NIH | $999,200 | |
Project Title: 7HP349, an Integrin Activator to Treat Patients with anti-PD-1 Resistant Solid Tumors | ||||
2021 | 1 | NIH | $297,724 | |
Project Title: Integrin Activation to Augment SARS-CoV-2 Vaccination | ||||
2021 | 2 | NIH | $2,000,000 | |
Project Title: Development of 7HP349, an Oral Integrin Activator to Enhance Therapeutic Responses to Immune Checkpoint Inhibitors |
Key People / Management
Upendra K Marathi -- Founder, President and CEO
Joseph Bailes -- Advisor & ManageJoseph Bailes, MD, Advisor & Manage
Richard Dixon -- Co-Founder & Manager
Lionel Lewis -- Chief Medical Officer
Jason Luke -- Advisor
Peter Vanderslice -- Advisor & Collaborator, co-founder
Daniel D Von Hoff -- Advisor & Collaborator
Robert Williams -- Media Contact
Darren G Woodside -- Advisor & Collaborator
Joseph Bailes -- Advisor & ManageJoseph Bailes, MD, Advisor & Manage
Richard Dixon -- Co-Founder & Manager
Lionel Lewis -- Chief Medical Officer
Jason Luke -- Advisor
Peter Vanderslice -- Advisor & Collaborator, co-founder
Daniel D Von Hoff -- Advisor & Collaborator
Robert Williams -- Media Contact
Darren G Woodside -- Advisor & Collaborator